Biohaven says FDA roadblocks leave rare disease patients in limbo

An FDA rejection last year for a rare disease drug from Biohaven reflects the amount of work left to get patients the treatments they need, the company says.

By Michael Gibney • Feb. 26, 2026

China’s biopharma advance draws financial investment

Experts are still keeping a close eye on geopolitical uncertainties, but licensing deals are turning into monetary growth.

By Kelly Bilodeau • Feb. 25, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Will the FDA yank mRNA vaccines?

Adding increased obstacles and sowing safety doubts may be enough to chill mRNA vaccine use and development.

By Alexandra Pecci • Feb. 24, 2026

How does the FDA really feel about psychedelics? We could soon find out.

Compass Pathways’ psilocybin-based drug is edging closer to an approval but faces mixed signals from officials.

By Kelly Bilodeau • Feb. 23, 2026

Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.

Moderna’s clash with U.S. health agencies over its flu shot reflects a difficult time for vaccinemakers, but many are still playing the waiting game.

By Michael Gibney • Feb. 19, 2026

Pharma could be on the cusp of finally breaking the blood-brain barrier

Denali’s brain shuttle technology is poised for a potential landmark approval in April, and other options are gaining ground. 

By Kelly Bilodeau • Feb. 18, 2026

More drugmakers are turning to cancer combos. Will it help patients live longer?

Researchers are increasingly trying multi-pronged approaches to stop tumors in their tracks, leaving monotherapies to the wayside.

By Kelly Bilodeau • Feb. 17, 2026

Ovid takes another big swing in neuroscience under a new CEO

After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.

By Meagan Parrish • Feb. 13, 2026

Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

The pharma giant’s acquisition of in vivo CAR-T specialist Orna Therapeutics follows similar deals from AbbVie, Gilead, Bristol Myers Squibb and AstraZeneca.

By Michael Gibney • Feb. 12, 2026

A protein model designed for space could expand pharma’s definition of ‘druggability’

A computational biology company that started in space tech is looking to change how biopharma finds disease targets by modeling how proteins behave.

By Michael Gibney • Feb. 11, 2026

In a tough market, biotechs can be their own worst enemy

Even with sound science, startups can struggle to make their candidates go the distance.

By Alexandra Pecci • Feb. 10, 2026

New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond

Emerging tests offer a bridge to pharma aiming to treat neurodegenerative diseases in their earlier stages.

By Kelly Bilodeau • Feb. 9, 2026

Investors crave safer, market-ready biotech bets, widening the early-stage funding gap

In these difficult financial times, venture capital dollars favor later-stage biotechs, forcing drugmakers with earlier-stage candidates to find alternative funding routes.

By Michael Gibney • Feb. 3, 2026

Mirum doubles down on diversified rare disease strategy

With the purchase of biotech Bluejay, Mirum stays focused on building a company with a broad pipeline and portfolio devoted to rare diseases.

By Alexandra Pecci • Feb. 3, 2026

Pharma’s outlook in 2026: Smoother sailing ahead?

After a turbulent year, the industry has a clearer picture of its new landscape and how to navigate the challenges and opportunities ahead. 

By Meagan Parrish • Jan. 30, 2026

Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential

The promising anti-inflammation target could be the next big thing in cardiovascular and other diseases.

By Alexandra Pecci • Jan. 29, 2026

Has Novavax cracked the code for survival in the vaccine arena?

The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.

By Meagan Parrish • Jan. 28, 2026

A potential gene therapy for heart failure is an approach decades in the making

Medera’s mid-stage heart failure gene therapy leverages a “master switch” that could widen the aperture of genetic medicine.

By Michael Gibney • Jan. 27, 2026

Biopharma layoffs surged last year, but 2026 is a chance to turn the page

Companies are adjusting to turbulence in the U.S. market, and more traditional job loss factors will likely be at play in the coming year.

By Kelly Bilodeau • Jan. 26, 2026

Big Pharma shops Chinese biotechs to stock GLP-1 pipelines

Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.

By Alivia Kaylor • Jan. 23, 2026

US drug pricing policies are ‘red lights’ for investors, and China beckons

Pricing policies like most-favored nation and the Inflation Reduction Act, as well as a destabilized FDA, are pushing investors to look outside the U.S.

By Michael Gibney • Jan. 22, 2026

Cancer R&D is thriving. Here are the areas to watch in 2026.

ADCs, radioligand therapies and multispecifics are leading the way in cancer innovation.

By Kelly Bilodeau • Jan. 21, 2026

The clinical candidates pharma execs are tracking

Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.

By Meagan Parrish • Jan. 16, 2026

It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?

The “trauma” faced by pharma execs in 2025 kept M&A at a low simmer, experts say, but as predictability returns, dealmaking could be turned up.

By Michael Gibney • Jan. 15, 2026

A biotech’s snakebite pill is drawing the US military’s interest

Backed by the Department of Defense, Ophirex is developing the first oral snakebite treatment, making on-the-ground treatment possible for the first time.

By Alexandra Pecci • Jan. 13, 2026